Cargando…

Treatment of Myelofibrosis: Old and New Strategies

Myelofibrosis (MF) is a BCR-ABL1–negative myeloproliferative neoplasm that is mainly characterised by reactive bone marrow fibrosis, extramedullary haematopoiesis, anaemia, hepatosplenomegaly, constitutional symptoms, leukaemic progression, and shortened survival. As such, this malignancy is still o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iurlo, Alessandra, Cattaneo, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428134/ https://www.ncbi.nlm.nih.gov/pubmed/28579852 http://dx.doi.org/10.1177/1179545X17695233

Ejemplares similares

Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
por: Iurlo, Alessandra, et al.
Publicado: (2022)

P1002: PROTEOMIC SCREENING IDENTIFIES MEGAKARYOCYTE DERIVED PF4/CXCL4 AS A CRITICAL DRIVER OF MYELOFIBROSIS
por: Malara, Alessandro, et al.
Publicado: (2023)

An unusual type of myeloid sarcoma localization following myelofibrosis: A case report and literature review
por: Orofino, Nicola, et al.
Publicado: (2017)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
por: Cattaneo, Daniele, et al.
Publicado: (2022)

New Perspectives on Polycythemia Vera: From Diagnosis to Therapy
por: Iurlo, Alessandra, et al.
Publicado: (2020)

P1018: TREND OF CIRCULATING CD34+ CELLS IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB
por: Cattaneo, D., et al.
Publicado: (2022)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

P989: NEWLY IDENTIFIED ROLES FOR PIEZO1 MECHANOSENSOR IN CONTROLLING NORMAL MEGAKARYOCYTE DEVELOPMENT AND IN PRIMARY MYELOFIBROSIS
por: Abbonante, Vittorio, et al.
Publicado: (2023)

Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options
por: Iurlo, Alessandra, et al.
Publicado: (2019)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022)

Immune Dysregulation and Infectious Complications in MPN Patients Treated With JAK Inhibitors
por: Cattaneo, Daniele, et al.
Publicado: (2021)

The evolving treatment paradigm in myelofibrosis
por: Mesa, Ruben A.
Publicado: (2013)

New Markers of Disease Progression in Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2021)

Focus on Osteosclerotic Progression in Primary Myelofibrosis
por: Spampinato, Mariarita, et al.
Publicado: (2021)

Next Generation Therapeutics for the Treatment of Myelofibrosis
por: Tremblay, Douglas, et al.
Publicado: (2021)

Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies
por: Naymagon, Leonard, et al.
Publicado: (2017)

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2016)

Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience
por: Cattaneo, Daniele, et al.
Publicado: (2021)

Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology
por: Eran, Zimran, et al.
Publicado: (2019)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
por: Ostojic, Alen, et al.
Publicado: (2012)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

Definition and management of ruxolitinib treatment failure in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2014)

Standard care and investigational drugs in the treatment of myelofibrosis
por: Barraco, Daniela, et al.
Publicado: (2019)

Momelotinib: an emerging treatment for myelofibrosis patients with anemia
por: Chifotides, Helen T., et al.
Publicado: (2022)

Emerging Treatment Options for Myelofibrosis: Focus on Anemia
por: Sastow, Dahniel, et al.
Publicado: (2023)

A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
por: Maffioli, Margherita, et al.
Publicado: (2022)

Murine Models of Myelofibrosis
por: Jacquelin, Sebastien, et al.
Publicado: (2020)

Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future
por: Duminuco, Andrea, et al.
Publicado: (2023)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2023)

Ponatinib as a Valid Alternative Strategy in Patients with Blast Crisis-Chronic Myeloid Leukemia Not Eligible for Allogeneic Stem Cells Transplantation and/or Conventional Chemotherapy: Report of a Case
por: Bucelli, Cristina, et al.
Publicado: (2017)

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
por: Rumi, Elisa, et al.
Publicado: (2020)

Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review
por: Barozzi, Enrico, et al.
Publicado: (2022)

Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms
por: Bose, Prithviraj, et al.
Publicado: (2020)

The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
por: Palmer, Jeanne, et al.
Publicado: (2020)

Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis
por: Perram, Jacinta, et al.
Publicado: (2022)

Novel therapeutics for myelofibrosis
por: Lee, Sung-Eun
Publicado: (2023)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d3114064f6k4sdtphaac5d1a76